Key facts
- Notable investors include Addor Capital, Grandway Capital, Luminous Ventures, Moutai (Guizhou) Private Equity Fund Management, Tachem — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for EnjoSim Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for EnjoSim Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EnjoSim Medical
Developer of self-administration systems designed to support the drug and device needs of patients. The company offers high-precision pen injection devices adapted to biological agents such as insulin, GLP-1, growth hormone, and follicle-stimulating hormone, thereby enabling patients to with clinical needs to self-administer medicine at home with self-injection pens.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- enjosim.com/
- Ownership
- Privately Held (backing)
EnjoSim Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EnjoSim Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EnjoSim Medical in its N-PORT filings yet. We sweep new filings monthly.